Advanced

Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer.

Larsson, Rikard; Mongan, Nigel; Johansson, M C; Shcherbina, Liliya LU ; Abrahamsson, Per-Anders LU ; Gudas, L; Sterner, Olov and Persson, Jenny L LU (2011) In Current Medicinal Chemistry 18. p.4440-4453
Abstract
Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and... (More)
Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and co-activator recruitment of the ligand-receptor complex; abiraterone, an orally administered drug that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17; and several newer cytotoxic drugs (epothilones, satraplatin). Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease. We also discuss potential molecular targets for new drug candidates for the treatment of metastatic PCa. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Current Medicinal Chemistry
volume
18
pages
4440 - 4453
publisher
Bentham Science Publishers
external identifiers
  • WOS:000299011500002
  • PMID:21864277
ISSN
0929-8673
language
English
LU publication?
yes
id
a9e415ff-123a-4d02-abf9-f112fa25aae8 (old id 2150730)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21864277?dopt=Abstract
date added to LUP
2011-09-04 22:45:28
date last changed
2016-11-17 13:34:58
@misc{a9e415ff-123a-4d02-abf9-f112fa25aae8,
  abstract     = {Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and co-activator recruitment of the ligand-receptor complex; abiraterone, an orally administered drug that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17; and several newer cytotoxic drugs (epothilones, satraplatin). Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease. We also discuss potential molecular targets for new drug candidates for the treatment of metastatic PCa.},
  author       = {Larsson, Rikard and Mongan, Nigel and Johansson, M C and Shcherbina, Liliya and Abrahamsson, Per-Anders and Gudas, L and Sterner, Olov and Persson, Jenny L},
  issn         = {0929-8673},
  language     = {eng},
  pages        = {4440--4453},
  publisher    = {ARRAY(0x99645b8)},
  series       = {Current Medicinal Chemistry},
  title        = {Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer.},
  volume       = {18},
  year         = {2011},
}